Sign in
Taking peoplePhase 2

Proton radiation after surgery for thymus epithelial tumors

Tests proton radiation after surgery in adults with advanced thymus epithelial tumors.

Key facts

Who runs it
Jian Chen
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor
Status
Recruiting
Phase
Phase 2
People taking part
55 people, planned
Started
6 May 2024
Expected to end
28 Feb 2027
Type of study
Interventional
Treatments tested
  • Proton radiotherapy
  • combined platinum based chemotherapy
Record updated
13 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage II-III thymus epithelial tumors who had surgery and need radiation afterwards. They will get proton radiotherapy after surgery.

Age
18 to 70 years
Sex
All sexes
Disease stage
Stage II-III (Masaoka-Koga) thymus epithelial malignancy, locally advanced. Surgery removed the tumor with no residual disease seen under the microscope (R0) or only microscopic residual disease (R1). ECOG score 0-2, which means able to care for yourself. Expected survival of at least 6 months.
Earlier treatment
Must have had radical surgery and need radiation after surgery. Cannot have had prior chest radiation therapy or radioactive seed implants.

Main reasons for not taking part

  • Other cancer that is not under control
  • Large amount of fluid around the lungs or heart
  • Pacemaker or metal implants that affect or are affected by radiation
  • HIV positive, active syphilis, or hepatitis needing antiviral treatment that cannot be given
  • Serious heart, lung or immune disease, or high sensitivity to radiation

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patients with stage II-III (Masaoka-Koga) thymus epithelial malignancies without a history of thoracic radiation therapy, who have undergone radical surgery and have a definite pathological diagnosis, and undergone surgery for R0 (no microscopic residual disease) or R1 (microscopic residual disease) resection, and have indication of postoperative radiation therapy
  • Sign informed consent
  • Between the ages of 18 and 70
  • ECOG general status score of 0-2
  • The expected survival is at least 6 months
  • Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1>25%, DLCO>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin <1.5 times the upper limit of normal value, and AST, ALT<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary protein <2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less

Who cannot take part

  • Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs
  • Chest radiation therapy or radioactive particle implantation history
  • HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis
  • Complicated with other malignant tumors that have not been controlled
  • Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area
  • A history of mental illness may hinder the completion of treatment
  • With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy
  • Have large quantity of pleural or pericardial effusion
  • Other circumstances that the physician considers inappropriate to participate in clinical study

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was overall survival and cause-specific survival.

The group in the trial

  • Study armTreatment being tested

    Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.

    Treatment: Proton radiotherapy and combined platinum based chemotherapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective Phase II Clinical Study of R0/R1 Post-operative Proton Radiation Therapy for Thymus Epithelial Malignancies
Plain-language title
Proton radiation after surgery for thymus epithelial tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06311968, who can take part
Record updated
13 June 2025